Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-01-04 @ 5:39 AM
Study NCT ID:
NCT03067935
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-05-21
First Post:
2017-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Individual Patient Expanded Access-Glembatumumab Vedotin
Sponsor:
Celldex Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2017-02-23
First Submit QC Date:
None
Study First Post Date:
2017-03-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-05-17
Last Update Post Date:
2018-05-21
Last Update Post Date Type:
ACTUAL